Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.

Also called NCT01203111

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 207 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01203111
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01203111. Non-randomized; no masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2012-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
Acronym
CHANGING
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
INSULIN GLARGINE
Intervention (Drug)
INSULIN GLULISINE
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01203111
Content hash
04b58745cfef65de4718dad1447c1dbde3c1c46b3fd4fd7721f9311145da878c